Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 195 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TLC Clear all
Completed Not applicable Interventional Results available

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

NCT01721226
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention
Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

NCT01070797
View directory record Official record
Conditions
Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions
Multi-virus Specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 7, 2026, 3:38 PM EDT
Recruiting Phase 1 Interventional

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

NCT06193759
View directory record Official record
Conditions
Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Embryonal Brain Tumor Not Otherwise Specified, Ependymoma
Interventions
Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy
Biological · Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 7, 2026, 3:38 PM EDT
Withdrawn Not applicable Interventional

Intensive Lifestyle Intervention for Type 2 Diabetics: The KP TLC Pilot

NCT01484353
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Coronary Health Improvement Project Program
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT04855305
View directory record Official record
Conditions
Interstitial Lung Diseases
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

NCT01333046
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

IT-Supported Early Treatment Of Childhood Overweight

NCT01188616
View directory record Official record
Conditions
Childhood Obesity, Technology Based Obesity Intervention
Interventions
Telephone Linked Care-HEAT (TLC-HEAT)
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
9 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Sep 7, 2026, 3:38 PM EDT
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

Hyperhidrosis in Patients With Amputations-Botox

NCT03236012
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A (Botox)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance

NCT01373242
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
Interventions
Liquid peanut extract (Peanut SLIT)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 7, 2026, 3:38 PM EDT
Recruiting Phase 2 Interventional

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 7, 2026, 3:38 PM EDT
Completed No phase listed Observational Results available

DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS

NCT02675075
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Not applicable Interventional

Residential Ventilation Systems and Filtration for Asthma Control in Adults

NCT06098287
View directory record Official record
Conditions
Asthma, Pollution; Exposure
Interventions
Residential mechanical ventilation system (Exhaust), Residential mechanical ventilation system (CFIS) and air filtration upgrades, Residential mechanical ventilation system (ERV) and air filtration upgrades
Device
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).

NCT00058604
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Lymphoproliferative Disorders
Interventions
Intravenous injection of EBV specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

NCT00002663
View directory record Official record
Conditions
EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Biological
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

NCT00953420
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Docetaxel, Carboplatin, Dexamethasone, EBV-specific cytotoxic T lymphocytes, G-CSF or Peg-GCSF
Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Not applicable Interventional

Can Computer-based Telephone Counseling Improve Long-term Adherence to Strength Training in Elders With Knee OA?

NCT01394874
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 7, 2026, 3:38 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

NCT02682147
View directory record Official record
Conditions
Emphysema
Interventions
Sildenafil
Drug
Lead sponsor
Eric A. Hoffman
Other
Eligibility
25 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 7, 2026, 3:38 PM EDT
Terminated Phase 1 Interventional

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

NCT02231853
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CML (Chronic Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), Acute Lymphoblastic Leukemia, AML (Acute Myelogenous Leukemia)
Interventions
MVST, MVSTr
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients

NCT00085930
View directory record Official record
Conditions
Neuroblastoma
Interventions
EBV specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 7, 2026, 3:38 PM EDT
Not listed Phase 1 Interventional

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

NCT03192462
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
multiTAA specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 7, 2026, 3:38 PM EDT
Completed Early Phase 1 Interventional

Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)

NCT02710162
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Micro Mouth Pressure Meter, Iowa Oral Performance Instrument, Electrical Impedance Myography, Capsaicin, Videofluoroscopic Swallowing Study, Pulmonary Function Testing, Swallowing Related Quality of Life Questionnaire, Functional Oral Intake Scale, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Eating Assessment Tool-10, Communicative Effectiveness Survey, The Center for Neurologic Studies Bulbar Function Scale
Device · Drug · Procedure + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 7, 2026, 3:38 PM EDT
Withdrawn Phase 1 Interventional

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

NCT03768310
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions
CD19.CAR-multiVST for Group A, CD19.CAR-multiVST for Group B
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 7, 2026, 3:38 PM EDT